1.0Cardiovascular Journal of Africahttps://cvja.co.za/journalEvaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africarich600338<blockquote class="wp-embedded-content" data-secret="9zGKzZkOs5"><a href="https://cvja.co.za/journal/cvja-2026-015/">Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://cvja.co.za/journal/cvja-2026-015/embed/#?secret=9zGKzZkOs5" width="600" height="338" title="“Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran” — Cardiovascular Journal of Africa" data-secret="9zGKzZkOs5" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.